Correction to: *Scientific Reports* 10.1038/s41598-020-58362-3, published online 30 January 2020

In Figure 5A, the chemical structure is incorrect. As a result, the Figure legend,

"AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H~2~O~2~ in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment."

should read:

"AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures^37^ (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H~2~O~2~ in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment."

The correct Figure 5 and its accompanying legend appear below as Figure [1](#Fig1){ref-type="fig"}.Figure 1AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures^37^ (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H2O2 in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.
